We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“These results indicate that temporarily inhibiting the action of glucocorticoids through pharmacological inhibitors can substantially boost the effectiveness of growth factor-based regenerative therapies. If validated in humans, this strategy could have a significant impact on the treatment of heart failure.”
“Deletion of the glucocorticoid receptor has been shown to increase the ability of heart muscle cells to replicate following myocardial infarction, promoting a process of heart regeneration within a few weeks. Similar results have also been obtained through the administration of a GR receptor inhibitor drug already approved for clinical use in humans.”
“Our study shows that blocking the glucocorticoid receptor pharmacologically can remove this brake on cardiomyocyte regeneration. We have seen that, in preclinical models, inhibiting this receptor restores the cardiomyocytes' response to growth factors, thereby stimulating heart cell proliferation even in later postnatal stages and adulthood.”
May warrant GR antagonist trials to boost post-MI regeneration; extends recent epigenetic suppressor findings but should not yet change practice.
No takes yet. Share an insight, caveat, or question.
Celik et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: